Literature DB >> 2055736

Comparison of the rates of adverse drug reactions. Ionic contrast agents, ionic agents combined with steroids, and nonionic agents.

G L Wolf1, M M Mishkin, S G Roux, E F Halpern, J Gottlieb, J Zimmerman, J Gillen, C Thellman.   

Abstract

The influence of ionic agents alone, of diatrizoate plus two oral doses of methylprednisolone premedication, and of a nonionic agent (iohexol) upon the frequency and severity of adverse drug reactions (ADRs) was compared in ten hospitals during three separate time periods from 1985 to 1989. Nonionic agents were found to reduce significantly total ADRs; 52 of 8857 patients receiving nonionic agents experienced reactions, versus 263 of 6006 patients for ionics (P less than .0001). The frequency of reactions classed as mild (2.9% for ionic agents versus 0.476 for nonionic agents: P less than .001), moderate (1.2% versus 0.1%; P less than .001), or severe (0.37% versus 0.01%; P less than .001), also favored nonionic agents. Steroid premedication provided some protection, but iohexol was significantly better with respect to mild reactions (2.9% versus 0.4%, P less than .001), moderate reactions (0.9% versus 0.1%, P less than .01), and severe reactions (0.25% versus 0.01%, P less than .01). The contrast medium was the greatest risk factor for adverse reaction (odds ratio 7.3), while prior contrast reaction (odds ratio 6.25), and hay fever (odds ratio 2.3) were found to be significant independent risks. We conclude that nonionic agents are safer for intravenous use than ionic agents given alone or with corticosteroid premedication.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055736     DOI: 10.1097/00004424-199105000-00003

Source DB:  PubMed          Journal:  Invest Radiol        ISSN: 0020-9996            Impact factor:   6.016


  13 in total

Review 1.  Reactions to radiocontrast material. Anaphylactoid events in radiology.

Authors:  P L Lieberman; R L Seigle
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist.

Authors:  Jeffrey J Pasternak; Eric E Williamson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

3.  Adverse reactions to intravascular contrast agents.

Authors:  Peter Dawson
Journal:  BMJ       Date:  2006-09-30

4.  Safety of 1000 CT-guided steroid injections with air used to localize the epidural space.

Authors:  A Chang; S Pochert; C Romano; A Brook; T Miller
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-13       Impact factor: 3.825

Review 5.  Adverse reactions to iodinated contrast media.

Authors:  Wendy Bottinor; Pritam Polkampally; Ion Jovin
Journal:  Int J Angiol       Date:  2013-09

Review 6.  Current understanding of contrast media reactions and implications for clinical management.

Authors:  Marc J Meth; Howard I Maibach
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

7.  A clinical study of cutaneous adverse reactions to nonionic contrast media in Korea.

Authors:  Kyung Eun Jung; Jimin Chung; Byung Cheol Park; Keum Nahn Jee; Young Koo Jee; Myung Hwa Kim
Journal:  Ann Dermatol       Date:  2012-02-02       Impact factor: 1.444

8.  The prevention of anaphylactoid reactions to iodinated radiological contrast media: a systematic review.

Authors:  Anthony Delaney; Andrew Carter; Malcolm Fisher
Journal:  BMC Med Imaging       Date:  2006-04-27       Impact factor: 1.930

9.  Influence of MRI contrast media on histamine release from mast cells.

Authors:  Tomasz Kun; Lucjusz Jakubowski
Journal:  Pol J Radiol       Date:  2012-07

10.  Changes in risk of immediate adverse reactions to iodinated contrast media by repeated administrations in patients with hepatocellular carcinoma.

Authors:  Naoto Fujiwara; Ryosuke Tateishi; Masaaki Akahane; Masataka Taguri; Tatsuya Minami; Shintaro Mikami; Masaya Sato; Koji Uchino; Kouji Uchino; Kenichiro Enooku; Yuji Kondo; Yoshinari Asaoka; Noriyo Yamashiki; Tadashi Goto; Shuichiro Shiina; Haruhiko Yoshida; Kuni Ohtomo; Kazuhiko Koike
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.